letrozole
information and resources from the National Cancer Institute
NCI Thesaurus | letrozole
A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis. In estrogen-dependent breast cancers, anastrozole may inhibit tumor growth. NCI Thesaurus | letrozole
A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis. In estrogen-dependent breast cancers, anastrozole may inhibit tumor growth.
Femara Novartis Jan 17 2003
Femara
First-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer.
Novartis Jan 10 2001
Femara
Treatment of advanced breast cancer in postmenopausal women.
Novartis Jul 25 1997
|
|
|
|
news articles
Patients Have Longer Disease-Free Survival on Letrozole When They ... Mar 27, 2006
DG News NICE, FRANCE -- March 27, 2006 -- Breast cancer patients treated with letrozole (Femara) have a longer disease-free survival if their tumours are positive for ...
BIG 1-98: Letrozole Reduces Recurrence More Than Tamoxifen in ... Mar 27, 2006
DG News NICE, FRANCE -- March 27, 2006 -- Patients treated with letrozole are less likely to have a recurrence of breast cancer than are those who are treated with ...
Femara (letrozole) Approved in Germany as Initial Therapy for ... Mar 20, 2006
DG News BASEL, SWITZERLAND -- March 20, 2006 -- Novartis announced today that Femara® (letrozole) has received approval in Germany for use after surgery in ...
Early Use of Zoledronic Acid Prevents Letrozole-Related Bone Loss Mar 24, 2006
Medscape (subscription) March 24, 2006 (Nice, France) — Women who receive zoledronic acid (Zometa) at the initiation of breast cancer treatment with letrozole (Femara) have less ...
Letrozole's Benefit for Breast Cancer Patients Mar 15, 2006
eMaxHealth.com, The complete analysis of data from an international trial of the drug letrozole (Femara) confirms earlier reports that the drug reduced the recurrence of ...
A 62-Year-Old Woman With a New Diagnosis of Breast Cancer Mar 21, 2006
Journal of American Medical Association (subscription), The nonsteroidal compounds anastrozole and letrozole are reversible inhibitors of aromatase, while the steroidal agent exemestane is an irreversible ...
International Approvals: Femara and Remicade Mar 27, 2006
Medscape (subscription) March 27, 2006 — Germany's Federal Institute for Drugs and Medical Devices has approved letrozole for the adjuvant treatment of postmenopausal women with ...
ZO-FAST Trial Shows Early Use of Zoledronic Acid Prevents Bone ... Mar 22, 2006
DG News ...receptor-positive breast cancer have less bone loss if they start zoledronic acid (Zometa) therapy early in the course of their letrozole (Femara) treatment ...
New findings in breast cancer therapy described Mar 30, 2006
Therapeutics Daily (subscription) (press release), The third-generation aromatase inhibitors (AIs) anastrozole, exemestane, and letrozole offer new treatment options, although their efficacy has not been ...
Pay attention to your breasts Mar 11, 2006
Malaysia Star, A recent development in breast cancer treatment is the approval of a drug (in the United States) called letrozole as initial therapy for treatment of ...
New Clinical Data Show Benefits of Femara(R) for Women With Breast ... Mar 23, 2006
PR Newswire (press release), FRIMLEY, England, March 23 /PRNewswire-FirstCall/ -- Women with hormone-sensitive early breast cancer who switched to Femara(R) (letrozole, an aromatase ...
Femara® Approved In Germany As Initial Therapy For Postmenopausal ... Mar 25, 2006
Medical News Today (press release), Novartis has announced that Femara® (letrozole) has received approval in Germany for use after surgery in postmenopausal women with hormone-sensitive early ...
Termination Of Phase 3 Clinical Program With Oral Temsirolimus In ... Mar 20, 2006
Medical News Today (press release), ...to discontinue the HORIZON phase 3 clinical trial program of Wyeth's investigational drug temsirolimus oral tablets in combination with letrozole (Femara(R ...
Wyeth Pharma Discontinues Phase 3 Trial Of Temsirolimus Oral ... Mar 16, 2006
Trading Markets, ...announced that it would discontinue the HORIZON phase 3 clinical trial of its investigational drug temsirolimus oral tablets, combined with letrozole, on the ...
New Clinical Data Show Benefits of Femara(R) for Women With Breast ... Mar 23, 2006
DG News FRIMLEY, UK -- March 23, 2006 -- Women with hormone-sensitive early breast cancer who switched to Femara(R) (letrozole, an aromatase inhibitor) from placebo as ...
New Clinical Data Show Benefits of Femara for Women With Breast ... Mar 23, 2006
PharmaLive.com (press release), FRIMLEY, England, March 23, 2006 /PRNewswire-FirstCall/ -- Women with hormone-sensitive early breast cancer who switched to Femara(R) (letrozole, an aromatase ...
- Results Presented Today at Key European Breast Cancer Medical ... Mar 23, 2006
ITNews, Women with hormone-sensitive early breast cancer who switched to Femara(R) (letrozole, an aromatase inhibitor) from placebo as part of a landmark trial ...
New Clinical Data Show Benefits of Femara(R) for Women With Breast ... Mar 23, 2006
PR Inside (Pressemitteilung), The letrozole vs placebo arm of the study (presented at the 5th EBCC) involved 5187 postmenopausal women with ER+ and/or PgR+ or receptor-unknown who were ...
Wyeth: breast cancer prospects receive a blow Mar 23, 2006
Pharmaceutical Business Review Wyeth has discontinued a phase III trial of temsirolimus plus letrozole in metastatic post-menopausal hormone-receptor positive breast cancer. ...
Drug cuts chances of breast cancer returning, say Mar 24, 2006
Haber Sa?l?k, Femara, which costs £83 a month, is the trade name for letrozole, one of a group of drugs called aromatase inhibitors (AI) which reduce levels of oestrogen ...
Wyeth Terminates Phase 3 Clinical Program With Oral Temsirolimus ... Mar 16, 2006
Trading Markets, ...the termination of HORIZON phase 3 clinical trial program of its investigational drug temsirolimus oral tablets in combination with letrozole, a currently ...
Updated Guidelines for Treatment of Ovarian Cancer Mar 27, 2006
Cancer Consultants (press release), ...cancer was broadened to include Arimidex® (anastrozole), Avastin® (bevacizumab), Camptosar® (ironotecan), Ifex® (ifosfamide), and Femara® (letrozole). ...
Femara® approved in Germany as initial therapy for postmenopausal ... Mar 20, 2006
WebWire (press release), Basel, March 20, 2006 - Novartis announced today that Femara® (letrozole) has received approval in Germany for use after surgery in postmenopausal women with ...
Ind Swift Lab gets Australian certification Mar 22, 2006
India Infoline.com, These are Letrozole (Aromtase Inhibitor), Quetiapine Fumerate (Anti-Psychotic), Aripiprazole (Anti-Pshycotic) and Ropinirole (Parkinson Disease). ...
EBCC: Zometa with Femara Sooner Better Than Later in Keeping Bone Mar 23, 2006
MedPage Today, ...better than delayed Zometa at preserving bone mineral density in breast cancer patients treated with adjuvant Femara (letrozole), researchers said here. ...
Ind Swift Laboratories API facility gets TGA certification Mar 22, 2006
domain-B, It recently launched four new APIs — Letrozole (aromtase inhibitor), quetiapine fumerate (anti-psychotic), aripiprazole (anti-pshycotic) and ropinirole ...
New Data Show Zometa Increased Bone Mineral Density in Breast ... Mar 22, 2006
PharmaLive.com (press release), ...per year significantly increased bone mineral density (BMD) in postmenopausal women being treated with an aromatase inhibitor, Femara® (letrozole), in the ...
NCCN Announces Important Updates to Ovarian Cancer Clinical ... Mar 6, 2006
Genetic Engineering News, AstraZeneca), bevacizumab (Avastin, Genentech), irinotecan (Camptosar, Pfizer), ifosfamide (Ifex, Bristol Myers-Squibb) and letrozole (Femara, Novartis). ...
Testing Drugs On India's Poor 21 Dec 2005
CounterCurrents.org, In another incident, Sun Pharmaceuticals convinced doctors to prescribe Letrozole, a breast cancer drug, to more than 400 women as a fertility treatment in a ...
Drugs work on estrogen to fight cancer 21 Dec 2005
News 8 Austin, ...estrogen. There are three AIs approved by the FDA including anastrozole (Arimidex), exemestane (Aromasin) and letrozole (Femara). ...
Responses Similar with Letrozole and Tipifarnib in Breast Cancer ... Dec 16, 2005
DG News ANTONIO, TX -- December 16, 2005 -- Researchers found little difference in response among breast cancer patients when they were treated with letrozole with or ...
Femara (Letrozole) Approved for Early Invasive Breast Cancer Post ... Dec 8, 2005
DG News FRIMLEY, UK -- December 8, 2005 -- Post menopausal women with early invasive breast cancer can now benefit from Femara(R) (letrozole) immediately after surgery ...
Switch from Tamoxifen to Letrozole Results in Significant ... Dec 12, 2005
DG News SAN ANTONIO, TX -- December 12, 2005 -- Women who switched from using tamoxifen to letrozole as endocrine treatments for breast cancer have reported ...
Letrozole-Bevacizumab Combination Safe and Effective in Women with ... Dec 9, 2005
DG News SAN ANTONIO, TX -- December 9, 2005 -- More than half of women with locally advanced breast cancer who were treated with letrozole in combination with ...
Contraindication of Femara (Letrozole) in Premenopausal Women Nov 28, 2005
DG News ...discussions with Health Canada, Novartis is advising health care professionals of concerns about the use of the aromatase inhibitor Femara* (letrozole) for the ...
Fertility drug could be the cause of birth defects and ... Dec 20, 2005
Newstarget.com, Canadian health regulators have sent out a health alert regarding the drug letrozole, marketed under the brand name Femara, which is designed to treat breast ...
No Changes in Breast Density Seen in Response to Treatment with ... Dec 13, 2005
DG News SAN ANTONIO, TX -- December 13, 2005 -- Women receiving letrozole (Femara) as endocrine therapy following tamoxifen therapy to prevent breast cancer recurrence ...
Breast Cancer Patients Benefit from Treatment with Investigational ... Dec 12, 2005
DG News ...temisirolimus appears to increase time to progression of advanced breast cancer -- nearly doubling that time from 9.5 months for women taking letrozole to 18 ...
Avastin®/Femara® Combination May Be Promising for Advanced ... Dec 20, 2005
Cancer Consultants (press release), Sloan-Kettering Cancer Center in New York recently reported that the treatment combination of Avastin (bevacizumab) and Femara (letrozole) provide high rates ...
International Approvals: Femara, Xyrem, Duodopa Dec 12, 2005
Medscape (subscription) 12, 2005 — The UK Medicines and Healthcare Products Regulatory Agency has approved letrozole tablets for the adjuvant treatment of postmenopausal women with ...
Temsirolimus May Improve Effectiveness of Femara® in Advanced ... Dec 14, 2005
Cancer Consultants (press release), Researchers from Europe recently reported results from a phase II clinical trial indicating that the addition temsirolimus to Femara® (letrozole) resulted in ...
Five-Year Data from Austrian Trial Shows Significant Benefit in ... Dec 14, 2005
DG News ...other trials have shown that efficacy is improved when a patient is switched from tamoxifen to an aromatase inhibitor such as letrozole, anastrozole or ...
Breast Cancer Treatment Dec 16, 2005
Food Consumer, 139. Goss PE, Ingle JN, Martino S, et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast ...
SABCS: Femara Beneficial Even Years After Tamoxifen Ends Dec 9, 2005
MedPage Today, 9 - Taking the aromatase inhibitor Femara (letrozole) -- even years after stopping treatment with tamoxifen -- offers a "fantastic" benefit for women at risk ...
Few women could benefit from adjuvant therapy with aromatase ... Dec 6, 2005
Xagena.it, ...has demonstrated a small disease free-survival benefit when these patients receive an aromotase inhibitor, such as Femara ( Letrozole ), after completing 5 ...
UK Leads Europe and US in Milestone Post-op Breast Cancer ... Dec 7, 2005
PR Newswire (press release), Femara (letrozole) Approved for Early Invasive Breast Cancer Post-Surgery FRIMLEY, England, December 8 /PRNewswire-FirstCall/ -- Post menopausal women with ...
Novartis issues breast cancer drug warning Nov 30, 2005
CTV.ca, WASHINGTON — The manufacturer of a breast cancer drug, Letrozole, is warning fertility doctors that it has been associated with birth defects, a caution ...
HealthFirst-Health news Nov 30, 2005
ABC12.com, Novartis, the company that makes Letrozole, warns doctors that the drug has been linked to birth defects. Letrozole is approved ...
Combination of Avastin® and Femara® Shows Promise for Advanced ... Dec 12, 2005
Cancer Consultants (press release), Memorial Sloan-Kettering Cancer Center in New York recently reported that the treatment combination of Avastin (bevacizumab) and Femara (letrozole) may benefit ...
Temsirolimus (CCI-779) May Improve Effectiveness of Femara in ... Dec 15, 2005
Cancer Consultants (press release), ...from Europe recently reported results from a randomized, 3-arm, phase II study indicating that the addition temsirolimus to Femara® (letrozole) may improve ...
Femara® After Years of No Therapy Provides Benefits in Hormone ... Dec 15, 2005
Cancer Consultants (press release), Results from a clinical trial that compared Femara® (letrozole) to placebo after five years of tamoxifen for early breast cancer suggest that treatment with ...
* Results reported by the National Cancer Institute of Canada ... Dec 13, 2005
WebWire (press release), Basel, December 13, 2005 - Women with hormone-sensitive early breast cancer who switched to Femara? (letrozole) from placebo as part of a landmark trial ...
New clinical data show dramatic benefits of Femara* for women with ... Dec 13, 2005
Canada NewsWire (press release), 13 /CNW Telbec/ - Women with hormone-sensitive early breast cancer who switched to Femara(*) (letrozole) from placebo as part of a landmark trial experienced ...
Locally produced estrogen promotes fetal rat metatarsal bone ... Dec 6, 2005
Journal of Endocrinology The aromatase inhibitor letrozole (1 mM) and the pure estrogen receptor antagonist ICI 182 780 (10 mM) inhibited proliferation of HCS-2/8 chondrocytes by 20% (P ...
New Clinical Data Show Dramatic Benefits of Femara(R) for Women ... Dec 13, 2005
PR Newswire (press release), 13 /PRNewswire/ -- Women with hormone-sensitive early breast cancer who switched to Femara(R) (letrozole tablets) from placebo as part of a landmark trial ...
Safety Alert Issued for Off-Label Use of Breast Cancer Drug Nov 29, 2005
HealthCentral.com The drug letrozole (brand name Femara), which is often prescribed as a fertility aid, may cause birth defects and miscarriages, according to a Health Canada ...
National Digest Nov 30, 2005
Kansas City Star, WASHINGTON — The manufacturer of letrozole is warning fertility doctors that the breast cancer drug has been associated with birth defects. ...
Drug prescribed to aid fertility linked to defects, regulators say Nov 28, 2005
San Jose Mercury News, The drug letrozole, marketed under the brand name Femara, is approved to treat breast cancer in women who've undergone menopause. ...
Drug used in fertility has risk Nov 29, 2005
San Jose Mercury News, The drug letrozole, marketed under the brand name Femara, is approved to treat breast cancer in women who have gone through menopause. ...
Novartis Issues Breast Cancer Drug Warning Nov 29, 2005
ABC News WASHINGTON Nov 29, 2005 — The manufacturer of a breast cancer drug, letrozole, is warning fertility doctors that it has been associated with birth defects, a ...
Novartis issues breast cancer drug warning Nov 29, 2005
USA Today WASHINGTON (AP) — The manufacturer of a breast cancer drug, letrozole, is warning fertility doctors that it has been associated with birth defects, a caution ...
Novartis issues breast cancer drug warning Nov 29, 2005
Sify, Washington: Novartis, the manufacturer of breast cancer drug letrozole, is warning fertility doctors that it has been associated with birth defects, a caution ...
Govt medicine spending slammed as 'pathetic' Dec 5, 2005
Stuff.co.nz, ...these new investment decisions, Pharmac widened access to treatments for patients who had heart failure (candesartan), breast cancer (letrozole), nausea from ...
Canadian Regulators Warn Against Use of Femara as Fertility Drug Nov 30, 2005
CNN 29 - The aromatase inhibitor Femara (letrozole) -- approved as adjuvant breast cancer therapy in postmenopausal women -- can cause birth defects and ...
Anti-depressant prescriptions rising Dec 5, 2005
TVNZ, ...to these new investments, Pharmac widened access to treatments for patients who had heart failure (candesartan), breast cancer (letrozole), nausea from cancer ...
Wyeth working on new breast cancer drug Dec 8, 2005
CNN Patients who took only Femara, also known as letrozole, the standard treatment, survived for nine-and-a-half months, said Allen. ...
Breast Cancer Drug Femara May Cause Birth Defects Nov 30, 2005
FOX News WASHINGTON — The manufacturer of a breast cancer drug, letrozole, is warning fertility doctors that it has been associated with birth defects, a caution ...
ARIMIDEX (anastrozole) Featured in Studies Evaluating Impact of ... Dec 9, 2005
PharmaLive.com (press release), Also presented today (Poster # 2052) were initial findings from the Letrozole, Exemestane, and Anastrozole Pharmacodynamics (LEAP) trial, which provides direct ...
UK Leads Europe and US in Milestone Post-op Breast Cancer ... Dec 7, 2005
Boursorama, December 8 /PRNewswire-FirstCall/ -- Post menopausal women with early invasive breast cancer can now benefit from Femara(R) (letrozole) immediately after ...
UK Leads Europe and US in Milestone Post-op Breast Cancer ... Dec 7, 2005
PR Newswire UK (press release), Post menopausal women with early invasive breast cancer can now benefit from Femara(R) (letrozole) immediately after surgery following early approval of an ...
Spending on target, patient numbers growing Dec 5, 2005
Scoop.co.nz (press release), ...these new investment decisions, PHARMAC widened access to treatments for patients who had heart failure (candesartan), breast cancer (letrozole), nausea from ...
Health Canada, Novartis Issue Alert Against Off-Label Use of ... Nov 30, 2005
Kaiser network.org, ...company Novartis on Monday issued warnings against "off-label" use of the breast cancer treatment Femara, known generically as letrozole, to treat infertility ...
Femara gets approval for early adjuvant use in UK Dec 8, 2005
Pharma Times (subscription), The UK is the first country in Europe to approve the new indication, which makes Femara (letrozole) the only aromatase inhibitor cleared for use across the ...
Femara: Not a fertility drug Nov 30, 2005
myDNA.com, Femara (letrozole) is a medication authorized for use in Canada to treat breast cancer in women who are postmenopausal. Novartis Pharmaceuticals Canada Inc. ...
Breast cancer drug linked to birth defects Nov 30, 2005
The Advocate, The manufacturer of a breast cancer drug, letrozole, marketed under the brand name Femara, is warning fertility doctors that it has been associated with birth ...
National Briefs Nov 29, 2005
Winston-Salem Journal, Letrozole is approved for use only in postmenopausal women with breast cancer. ... Letrozole is marketed under the name Femara. It is manufactured by Novartis. ...
New Clinical Data Show Dramatic Benefits of Femara for Women with ... Dec 13, 2005
PharmaLive.com (press release), EAST HANOVER, NJ, December 13, 2005 /PRNewswire/ -- Women with hormone-sensitive early breast cancer who switched to Femara(R) (letrozole tablets) from placebo ...
Novartis Issues Breast Cancer Drug Warning Nov 29, 2005
CBS News ...(AP) The manufacturer of a breast cancer drug, letrozole, is warning fertility ... Letrozole is approved for use only in postmenopausal women with breast cancer. ...
Novartis Issues Breast Cancer Drug Warning Nov 29, 2005
Salon November 29,2005 | WASHINGTON -- The manufacturer of a breast cancer drug, letrozole, is warning fertility doctors that it has been associated with birth ...
Novartis Issues Breast Cancer Drug Warning Nov 29, 2005
Norman Transcript, The manufacturer of a breast cancer drug, letrozole, is warning fertility doctors that it has been associated with birth defects, a caution prompted by reports ...
Drug to aid fertility tied to defects, regulators warn Nov 29, 2005
Detroit Free Press, ...regulators. Letrozole, marketed under the name Femara, is approved to treat breast cancer in women who have undergone menopause. ...
Novartis warns about breast cancer drug use Nov 29, 2005
Miami Herald, ...a woman become pregnant. The drug, letrozole, is approved for use only in postmenopausal women with breast cancer. But there is ...
Canadians warned on drug misuse Nov 28, 2005
Arizona Daily Star, ...regulators. Letrozole, sold under the brand name Femara, is approved to treat breast cancer in women who have undergone menopause. ...
Novartis warns doctors Nov 30, 2005
NorthJersey.com, ...a woman become pregnant. The drug, letrozole, is approved for use only in post-menopausal women with breast cancer. But there is ...
Warning that breast cancer drug can harm fetus Nov 30, 2005
News-Medical.net, Health Canada along with drug company Novartis Pharmaceuticals Canada, have issued a warning concerning the drug Femara (letrozole), which is used to treat ...
Novartis Warns Doctors on Off-Label Femara Use Dec 1, 2005
Medscape (subscription) ZURICH (Reuters) Nov 30 - Novartis has warned doctors not to use its hormone-based breast cancer drug Femara (letrozole) to help women become pregnant after ...
Novartis Warns Doctors on Off-Label Femara Use Dec 1, 2005
Cancerpage.com, ZURICH NOV 30, 2005 (Reuters) - Novartis has warned doctors not to use its hormone-based breast cancer drug Femara (letrozole) to help women become pregnant ...
Swiss firm warns breast cancer drug can harm unborn children Nov 30, 2005
Japan Today, Wednesday. Letrozole, distributed by Novartis AG under the name Femera, is commonly used to prevent relapses of breast cancer. Animal ...
The effects of testosterone and estrogen on gonadectomized and ... Nov 25, 2005
Journal of Endocrinology The latter was blocked by co-administration of Sustanon with the non-steroidal aromatase inhibitor letrozole and was not seen when the non-aromatizable ...
|
|
